Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854213 | 0.96 | PARP1 (0.48) | HRH3HRH1KCNH2KDM4ENPC1 | |
| SCHEMBL853477 | 0.88 | HRH3 (0.52) | HRH3HRH1KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL853518 | 0.88 | HRH3 (0.48) | HRH3HRH1KCNH2PARP1ACP1 | |
| SCHEMBL853478 | 0.88 | HRH3 (0.46) | HRH3HRH1KCNH2KDM4EPARP1 | |
| SCHEMBL853849 | 0.88 | PARP1 (0.56) | HRH3HRH1KCNH2KDM4EPARP1 | |
| SCHEMBL855098 | 0.87 | HRH3 (0.51) | HRH3HRH1KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL855320 | 0.84 | HRH3 (0.44) | HRH3HRH1KCNH2KDM4EBCHE | |
| SCHEMBL854604 | 0.84 | PARP1 (0.61) | HRH3HRH1PARP1PARP3 | |
| SCHEMBL853155 | 0.84 | PARP1 (0.48) | HRH3HRH1KCNH2KDM4EPARP1 | |
| SCHEMBL854313 | 0.82 | HTR2A (0.49) | HRH3HRH1KCNH2KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432765-B1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-03-02 | — | — | EP | claimed |
| US-8592416-B2 | Isoquinolin-1 (2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-26 | — | — | US | claimed |
| US-20120157454-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | US | claimed |
| EP-2432765-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-03-28 | — | — | EP | claimed |
| WO-2010133647-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-25 | — | — | WO | claimed |
| EP-2432765-B1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-03-02 | — | — | EP | disclosed |
| US-8993594-B2 | Isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-20140045846-A1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-13 | — | — | US | disclosed |
| US-8592416-B2 | Isoquinolin-1 (2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-26 | — | — | US | disclosed |
| US-20120157454-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | US | disclosed |
| EP-2432765-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133647-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157454-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | PARP1, PARP2, PARP11 | HRH3 2671/4885HRH1 2585/4885KCNH2 4080/4885 |
| US-20140045846-A1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | PARP1, PARP2, PARP11 | HRH3 2671/4885HRH1 2585/4885KCNH2 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.